

Contact Information**Work**

Department of Selenoprotein Research
 National Institute of Oncology
 Building 11, Ráth György u. 7-9, 1122 Budapest, Hungary
 Tel: +36-1-224-8600/1352
 E-mail: uri.katalin@oncol.hu
 Web: <https://bit.ly/3ilY3vJ>

Education

Date	Degree	Institution	Description
2009	BSc.	University of Debrecen, Hungary	Specialization: Laboratory Biology
2011	MSc.	University of Debrecen, Hungary	Specialization: Biomedical and Pharmacology ,Thesis : Examination the metabolic effects of the 2nd generation antipsychotic drugs
2015	PhD.	University of Debrecen, Hungary	Laki Kálmán Doctoral School, Research topic: The role of the angiotensin-converting enzyme 2 (ACE2) in cardiovascular disease

Appointments/Affiliations

Date	Title	Institution
2021 - present	Affiliated researcher	Department of Medical Biochemistry and Biophysics, Karolinska Inst, Stockholm, Sweden
2021 - present	Biologist	Department of Selenoprotein Research, National Institute of Oncology, Budapest, Hungary
2018 - 2021	QC Analyst	Egis Pharmaceuticals PLC., Budapest, Hungary
2016 - 2018	Molecular Biologist	Istenhegyi Genediagnostic Center, Budapest, Hungary
2016	Assistant Research Fellow	Johannes Kepler University Linz, Institute of Biophysics, Linz, Ausztria
2015	Internship	Université Paris Diderot, Biomarkers and Heart Diseases, Paris, France
2014	Internship	National Institute of Health, Laboratory of Cancer Biology and Genetics, National Cancer Institute, Washinton, USA
2010-2011	Undergraduate Student Research	University of Debrecen, Faculty of Medicine, Institute of Cardiology, Division of Clinical Physiology, Debrecen, Hungary

Bibliometry

As of July 02, 2021, a total of 5 articles in PubMed, cited 222 times with h-index of 5 (Google Scholar) or cited 125 times with an h-index of 5 (Web Of Science).

Publications

Katalin Úri, Miklós Fagyas, Attila Kertész, Attila Borbély, Csaba Jenei, Orsolya Bene, Zoltán Csanádi, Walter J Paulus, István Édes, Zoltán Papp, Attila Tóth, Erzsébet Lizanecz Circulating ACE2 activity correlates with cardiovascular disease development. *Journal of the Renin-Angiotensin-Aldosterone System*, vol. 17, 4First Published December 1, 2016

Uri K, Fagyas M, Manyine Siket I, Kertesz A, Csanadi Z, Sandorfi G, Clemens M, Fedor R, Papp Z, Edes I, Toth A, Lizanecz E New Perspectives in the Renin-Angiotensin-Aldosterone System (RAAS) IV: Circulating ACE2 as a Biomarker of Systolic Dysfunction in Human Hypertension and Heart Failure. *PLOS ONE* 9:(4) p. e87845. (2014), DOI:10.1371/journal.pone.0087845

Fagyas M, Uri K, Siket IM, Darago A, Boczan J, Banyai E, Edes I, Papp Z, Toth A New Perspectives in the Renin-Angiotensin-Aldosterone System (RAAS) III: Endogenous Inhibition of Angiotensin Converting Enzyme (ACE) Provides Protection against Cardiovascular Diseases. *PLOS ONE* 9:(4) p. e93719. (2014), DOI:10.1371/journal.pone.0093719

Fagyas M, Uri K, Siket IM, Fulop GA, Csato V, Darago A, Boczan J, Banyai E, Szentkiralyi IE, Maros TM, Szerafin T, Edes I, Papp Z, Toth A New Perspectives in the ReninAngiotensin-Aldosterone System (RAAS) II: Albumin Suppresses Angiotensin Converting Enzyme (ACE) Activity in Human. *PLOS ONE* 9:(4) p. e87844. (2014), DOI:10.1371/journal.pone.0087844

Fagyas M, Uri K, Siket IM, Darago A, Boczan J, Banyai E, Edes I, Papp Z, Toth A New Perspectives in the Renin-Angiotensin-Aldosterone System (RAAS) I: Endogenous Angiotensin Converting Enzyme (ACE) Inhibition. *PLOS ONE* 9:(4) p. e87843. (2014), DOI:10.1371/journal.pone.0087843